Fluoxetine pretreatment effects pharmacokinetics of 3,4- methylenedioxymethamphetamine (MDMA, ECSTASY) in rat

Journal of Pharmaceutical Sciences

Volumn 97, Issue 4, 2008, Pages 1593-1605

  Upreti, Vijay V ^a   Eddington, Natalie D ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

Drug interaction; Fluoxetine; MDA; MDMA; P glycoprotein; Pharmacokinetics

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; DRUG METABOLITE; ELACRIDAR; FLUOXETINE; GLYCOPROTEIN P; ALCOHOL DEHYDROGENASE; CYP2D9 PROTEIN, RAT; CYTOCHROME P450 2D6;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ARTICLE; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ABUSE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG PENETRATION; DRUG TRANSPORT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KIDNEY CELL; MALE; MONOLAYER CULTURE; MOUSE; NEUROTOXICITY; NONHUMAN; RAT; SINGLE DRUG DOSE; SPRAGUE DAWLEY RAT; ANIMAL; BRAIN; DRUG INTERACTION; HUMAN; METABOLISM; PHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

3,4-METHYLENEDIOXYAMPHETAMINE; ALCOHOL OXIDOREDUCTASES; ANIMALS; BIOLOGICAL TRANSPORT; BRAIN; CACO-2 CELLS; CYTOCHROME P-450 CYP2D6; DRUG INTERACTIONS; FLUOXETINE; HUMANS; MALE; MICE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; P-GLYCOPROTEIN; RATS; RATS, SPRAGUE-DAWLEY;

EID: 43249126070     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21045     Document Type: Article

References (37)

1. Parrott AC. 2004. MDMA (3,4-Methylenedioxy-methamphetamine) or ecstasy: The neuropsycho-biological implications of taking it at dances and raves. Neuropsychobiology 50:329-335.
2. Seper J. 2000. Threat of 'ecstasy' reaching cocaine, heroin proportions. Wash Times 16:A3.
3. Landry MJ. 2002. MDMA: A review of epidemiologic data. J Psychoactive Drugs 34:163-169.
4. Schifano F, Oyefeso A, Webb L, Pollard M, Corkery J, Ghodse AH. 2003. Review of deaths related to taking ecstasy, England and Wales, 1997-2000. Br Med J 326:80-81.
5. Dowling GP, McDonough ET III, Bost RO. 1987. 'Eve' and 'Ecstasy'. A report of five deaths associated with the use of MDEA and MDMA. JAMA 257:1615-1617.
6. Gill JR, Hayes JA, deSouza IS, Marker E, Stajic M. 2002. Ecstasy (MDMA) deaths in New York City: A case series and review of the literature. J Forensic Sci 47:121-126.
7. Henry JA, Hill IR. 1998. Fatal interaction between ritonavir and MDMA. Lancet 352:1751-1752.
8. Schifano F. 2004. A bitter pill. Overview of ecstasy (MDMA, MDA) related fatalities. Psychopharma-cology (Berl) 173:242-248.
9. Karlovsek MZ, Alibegovic A, Balazic J. 2005. Our experiences with fatal ecstasy abuse (two case reports). Forensic Sci Int 147:S77-S80.
10. Henry JA, Jeffreys KJ, Dawling S. 1992. Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy"). Lancet 340:384-387.
11. Hegadoren KM, Baker GB, Bourin M. 1999. 3,4-Methylenedioxy analogues of amphetamine: Defining the risks to humans. Neurosci Biobehav Rev 23:539-553.
12. Cole JC, Sumnall HR. 2003. Altered states: The clinical effects of Ecstasy. Pharmacol Ther 98:35-58.
13. Ben-Abraham R, Szold O, Rudick V, Weinbroum AA. 2003. 'Ecstasy' intoxication: Life-threatening manifestations and resuscitative measures in the intensive care setting. Eur J Emerg Med 10:309-313.
14. Ropero-Miller JD, Goldberger BA. 1998. Recreational drugs. Current trends in the 90s. Clin Lab Med 18:727-746.
15. Maurer HH, Bickeboeller-Friedrich J, Kraemer T, Peters FT. 2000. Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs ('Ecstasy'). Toxicol Lett 112-113:133-142.
16. Kreth K, Kovar K, Schwab M, Zanger UM. 2000. Identification of the human cytochromes P450 involved in the oxidative metabolism of "Ecstasy"- related designer drugs. Biochem Pharmacol 59: 1563-1571.
17. Tucker GT, Lennard MS, Ellis SW, Woods HF, Cho AK, Lin LY, Hiratsuka A, Schmitz DA, Chu TY. 1994. The demethylenation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6). Biochem Pharmacol 47: 1151-1156.
18. Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brosen K. 1996. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 51:73-78.
19. McCann UD, Ricaurte GA. 1993. Reinforcing subjective effects of (+/-) 3,4-methylenedioxy-methamphetamine ("ecstasy") may be separable from its neurotoxic actions: Clinical evidence. J Clin Psychopharmacol 13:214-217.
20. Cohen RS. 1998. The love drug: Marching to the beat of ecstasy. 1st edition. New York: Haworth Medical Press.
21. Sanchez V, Camarero J, Esteban B, Peter MJ, Green AR, Colado MI. 2001. The mechanisms involved in the long-lasting neuroprotective effect of fluoxetine against MDMA (ecstasy)-induced degeneration of 5-HT nerve endings in rat brain. Br J Pharmacol 134:46-57.
22. Ramamoorthy Y, Yu AM, Suh N, Haining RL, Tyndale RF, Sellers EM. 2002. Reduced (+/-)-3,4-methylenedioxymethamphetamine (ecstasy) metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro. Biochem Pharmacol 63:2111-2119.
23. FDA 2006. Guidance for Industry: Drug interaction studies: Study design, data analysis, and implications for dosing and labeling. (Draft Guidance).
24. Zhang L, Strong JM, Qiu W, Lesko LJ, Huang SM. 2006. Scientific perspectives on drug transporters and their role in drug interactions. Mol Pharm 3:62-69.
25. Mann H, Ladenheim B, Hirata H, Moran TH, Cadet JL. 1997. Differential toxic effects of methamphetamine (METH) and methylenedioxy-methamphetamine (MDMA) in multidrug-resistant (mdrla) knockout mice. Brain Res 769:340-346.
26. Ketabi-Kiyanvash N, Weiss J, Haefeli WE, Mikus G. 2003. P-glycoprotein modulation by the designer drugs methylenedioxymethamphetamine, methyle-nedioxyethylamphetamine and paramethoxyam-phetamine. Addict Biol 8:413-418.
27. Bertelsen KM, Greenblatt DJ, Moltke LL. 2006. Apparent active transport of MDMA is not mediated by P-glycoprotein: A comparison with MDCK and Caco-2 monolayers. Biopharm Drug Dispos 27:219-227.
28. Clauwaert KM, Van Bocxlaer JF, De Letter EA, Van Calenbergh S, Lambert WE, De Leenheer AP. 2000. Determination of the designer drugs 3,4-methylenedioxymethamphetamine, 3,4-methyle-nedioxyethylamphetamine, and 3,4-methylene-dioxyamphetamine with HPLC and fluorescence detection in whole blood, serum, vitreous humor, and urine. Clin Chem 46:1968-1977.
29. Bailer AJ. 1988. Testing for the equality of area under the curves when using destructive measurement techniques. J Pharmacokinet Biopharm 16: 303-309.
30. Chu T, Kumagai Y, DiStefano EW, Cho AK. 1996. Disposition of methylenedioxymethamphetamine and three metabolites in the brains of different rat strains and their possible roles in acute serotonin depletion. Biochem Pharmacol 51:789-796.
31. Kankaanpaa A, Meririnne E, Lillsunde P, Seppala T. 1998. The acute effects of amphetamine derivatives on extracellular serotonin and dopamine levels in rat nucleus accumbens. Pharmacol Biochem Behav 59:1003-1009.
32. O'Loinsigh ED, Boland G, Kelly JP, O'Boyle KM. 2001. Behavioural, hyperthermic and neurotoxic effects of 3,4-methylenedioxymethamphetamine analogues in the Wistar rat. Prog Neuropsycho-pharmacol Biol Psychiatry 25:621-638.
33. Garrett ER, Seyda K, Marroum P. 1991. High performance liquid chromatographic assays of the illicit designer drug "Ecstasy", a modified amphetamine, with applications to stability, partitioning and plasma protein binding. Acta Pharm Nord 3: 9-14.
34. Altamura AC, Moro AR, Percudani M. 1994. Clinical pharmacokinetics of fluoxetine. Clin Pharmacokinet 26:201-214.
35. Tancer M, Johanson CE. 2007. The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl) 189:565-573.
36. Jones DC, Duvauchelle C, Ikegami A, Olsen CM, Lau SS, de la Torre R, Monks TJ. 2005. Serotonergic neurotoxic metabolites of ecstasy identified in rat brain. J Pharmacol Exp Ther 313:422-431.
37. Polli JE, Rekhi GS, Augsburger LL, Shah VP. 1997. Methods to compare dissolution profiles and a rationale for wide dissolution specifications for metoprolol tartrate tablets. J Pharm Sci 86:690-700.